Pakistan Medicines & Pharma IntelligenceMedicine data  •  Company portfolios  •  Price records
MedInfoBaseMedicines · Evidence · Intelligence
Home / Pharmaceutical company intelligence
Pharmaceutical company intelligence

Innvotek Pharmaceuticals

Pharmaceutical manufacturer · Pakistan

Database-driven profile Portfolio, price and regulatory-source intelligence derived from MedInfoBase records.
ShareSend this page
Regulatory & corporate identity

Company profile

Not yet verified
Company type
Pharmaceutical manufacturer
DRAP-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000487 54 linked products · source seen 10 Aug 2026 View source ↗
Location intelligence

Company location

Google Maps
Exact site not yet verified

MedInfoBase will not invent a factory or office location. The map appears after a sourced address, Place ID or verified embed URL is added.

Open in Google Maps ↗ The Google Maps search link uses the company name and available city/country context; it is not presented as a verified premises pin.
Intelligence snapshot

Portfolio at a glance

Not sales data · current MedInfoBase database view
Rx54product presentations
G37generic molecules
DF4dosage-form groups
TA11therapeutic areas
PKR54current price records
REG50registration numbers
Data coverage

How complete is this profile?

Current price coverage100%
products with a current official price
Source-linked coverage100%
products linked back to a source record
Unit-price parse coverage98%
priced packs safely normalized per unit
Comparable-market coverage93%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixInnvotek PharmaceuticalsShare of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/innvotek-pharmaceuticalsGenerated 10 Aug 2026Anti-infectives30 · 56%Cardiovascular5 · 9%Ophthalmology5 · 9%Reproductive & genitourinary3 · 6%CNS & mental health2 · 4%Vitamins, minerals & nutrition2 · 4%Oncology & immunology2 · 4%Other therapeutic areas5 · 9%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioInnvotek PharmaceuticalsDistribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/innvotek-pharmaceuticalsGenerated 10 Aug 202654presentationsTablet40 · 74%Drops8 · 15%Capsule5 · 9%Ointment1 · 2%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent-Market Price Position

Shows whether safely comparable products are below, near or above the market median unit price.

Equivalent-Market Price PositionInnvotek PharmaceuticalsCurrent company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/innvotek-pharmaceuticalsGenerated 10 Aug 202650comparable productsBelow market median18 · 36%Near market median26 · 52%Above market median6 · 12%Company median price position-2.2%Lowest-price equivalents4Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsInnvotek PharmaceuticalsCompanies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/innvotek-pharmaceuticalsGenerated 10 Aug 2026Nabiqasim Industries (Pvt) Ltd.,23 shared62% overlapAtco Laboratories Limited22 shared59% overlapEpharm Laboratories22 shared59% overlapValor Pharmaceuticals21 shared57% overlapTABROS PHARMA (PVT). LTD.21 shared57% overlapGenome Pharmaceuticals (Pvt.) Ltd,21 shared57% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

Anti-infectives30 products · 56%
Cardiovascular5 products · 9%
Ophthalmology5 products · 9%
Reproductive & genitourinary3 products · 6%
CNS & mental health2 products · 4%
Vitamins, minerals & nutrition2 products · 4%
Oncology & immunology2 products · 4%
Gastrointestinal & hepatology2 products · 4%
Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Fluoroquinolone antibacterials8 products · 15%
Antivirals4 products · 7%
Glaucoma medicines4 products · 7%
Macrolide antibacterials4 products · 7%
Antimalarials3 products · 6%
Beta blockers3 products · 6%
SSRI antidepressants2 products · 4%
Antifungals2 products · 4%
Formulation footprint

Dosage forms

Tablet40 products
Drops8 products
Capsule5 products
Ointment1 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
#1 InvofloxCiprofloxacin 4presentations 250 mg, 3 mg/mL, 500 mg, 750 mg · Tablet, Drops #2 BisorenBisoprolol fumarate 3presentations 10 mg, 2.5 mg, 5 mg · Tablet #3 ChimeClarithromycin 2presentations 250 mg, 500 mg · Tablet #4 DuzestFluoxetine 2presentations 10 mg, 20 mg · Tablet #5 InvolineLinezolid 2presentations 400 mg, 600 mg · Tablet #6 LetaseLetrozole 2presentations 2.5 mg · Tablet
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median1836% of comparable products
Near market median26within ±5% of median
Above market median612% of comparable products
Lowest-price equivalents4ties included
Company median price position -2.2% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
Xalanol -T 50 mcg/mLLatanoprost · Ophthalmic drops · 2.5ml PKR 289.36/mL-54.1% vs market median Incot 400 mgSulfamethoxazole · Tablet · 40x10's PKR 2.31/tablet-33.8% vs market median Misabon 200 mcgMisoprostol · Tablet · 10's PKR 14.30/tablet-30.8% vs market median Misabon 200 mcgMisoprostol · Tablet · 28's PKR 14.30/tablet-30.8% vs market median Bisoren 2.5 mgBisoprolol fumarate · Tablet · 14's PKR 2.95/tablet-30.5% vs market median
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

Nabiqasim Industries (Pvt) Ltd.,362 products · 118 generics 23shared generics Atco Laboratories Limited275 products · 94 generics 22shared generics Epharm Laboratories144 products · 67 generics 22shared generics Valor Pharmaceuticals218 products · 97 generics 21shared generics TABROS PHARMA (PVT). LTD.179 products · 64 generics 21shared generics Genome Pharmaceuticals (Pvt.) Ltd,149 products · 71 generics 21shared generics
Regulatory & price activity

Observed database signals

Registration numbers50
Price-history records58
Products with price history4
Source records with multiple versions0
Latest MedInfoBase verification9 Aug 2026
Latest effective price date1 Jul 2025
Latest source observation10 Aug 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Sponsored company campaign area · advertising must be clearly disclosed
Complete company portfolio

Products and presentations

5 results
Intelligence filter: Therapeutic areaOphthalmology Clear intelligence filters
Reset
BrandGenericStrengthFormPackRegistrationOfficial priceUnit priceMarket position
CAI Acetazolamide 250 mg Tablet 30's 089623 PKR 313.18 PKR 10.44/tablet Near median
Mydropic Tropicamide 1 % Ophthalmic drops 15ml 024192 PKR 212.76 PKR 14.18/mL Near median
Timotek Timolol 0.5 % Ophthalmic drops 5ml 024191 PKR 274.45 PKR 54.89/mL 55% above median
Xalanol -T Latanoprost 50 mcg/mL Ophthalmic drops 2.5ml 098395 PKR 723.40 PKR 289.36/mL 54% below median
Xalanol Eyes 2.5 ml Latanoprost 0.005 % Ophthalmic drops 2.5mlxl's 106337 PKR 683.56 — No comparator
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and DRAP-source records. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.